A robust triple-stage quadrupole mass spectrometer for high-throughput clinical LC–MS/MS

Importance of the topic

Accurate, precise and durable quantification of clinical biomarkers (small molecules, steroids and peptides) underpins clinical decision-making, therapeutic drug monitoring and toxicology. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) with stable isotope dilution combines sensitivity, selectivity and multiplexing required for complex biological matrices, but routine clinical laboratories also demand long-term robustness, low maintenance and high throughput. Demonstrating instrument stability across thousands of injections and multiple biomarker classes is therefore critical to adoption in high-volume clinical workflows.

Aims and study overview

This work evaluates the operational robustness, analytical stability and reproducibility of the Thermo Scientific TSQ Certis triple-stage quadrupole mass spectrometer across representative clinical assays. The study assessed performance for four biomarker classes—immunosuppressants, drugs of abuse, steroids and peptides—by tracking signal intensity (peak area), relative peak area ratios (analyte/IS), retention time stability and ion ratio consistency over extended injection sequences ranging from dozens to over ten thousand injections.

Methodology and experimental design

Key elements of the study design included:

• Matrices tested: whole blood (immunosuppressants, drugs of abuse), serum/plasma (steroids) and digested control plasma spiked with stable isotope-labeled (SIL) peptides.

Used instrumentation

Instrumentation explicitly used and reported in the study:

• Thermo Scientific TSQ Certis triple quadrupole mass spectrometer
• Thermo Scientific Vanquish Horizon UHPLC
• Thermo Scientific Vanquish Neo UHPLC (capillary-flow)
• Thermo Scientific OptaMax Plus HESI ion source
• Thermo Scientific OptiSpray ion source and column cartridges
• Hamilton Microlab STAR automated liquid handler
• DPX Technologies INTip filtration with Tip-on-Tip (ToT) technology
• Thermo Scientific TraceFinder, Xcalibur and Skyline-daily software for data processing

Main results and discussion

Overall findings demonstrated sustained instrument performance across diverse assays and extended sequences:

• Immunosuppressants: Long-term stability was demonstrated across 10,209 whole-blood injections after protein precipitation. Ascomycin (used as internal standard) showed a peak-area %RSD of 13.8% across the entire sequence without requiring ion transfer tube or sweep cone cleaning, indicating consistent ion transmission and source stability over prolonged operation.
• Drugs of abuse: In a continuous sequence of 455 whole-blood injections, several compounds (e.g., buprenorphine and lorazepam) exhibited peak-area RSDs below ~6.1% and ion ratio variability within ±20%, meeting common confirmatory toxicology criteria for quantitative workflows.
• Steroids: In 311 injections of steroid calibrators prepared with 0.05% BSA, internal standard peak-area %RSDs were below 17% across steroid analytes, supporting quantitative stability for serum/plasma steroid panels.
• Peptides: A multiplexed targeted peptide assay (35 SIL peptides representing 24 FDA-recognized protein biomarkers) over 71 injections showed retention time RSDs between 0.084% and 0.56% (33 peptides <0.5%), and 88% of peptides had peak-area RSD <10% across the sequence, indicating excellent chromatographic and quantitative reproducibility for capillary-flow peptide workflows.
• Method speed and throughput: Small-molecule methods ran in 3–9 minutes with rapid polarity switching; peptide assays ran in ~13 minutes, demonstrating suitability for high-throughput laboratory schedules.

These results collectively indicate the TSQ Certis provides stable MRM performance, reproducible retention times and acceptable ion ratio consistency across long analytical runs and multiple clinically relevant matrices, with minimal maintenance interventions.

Benefits and practical applications

The demonstrated robustness translates into several practical advantages for clinical and high-throughput research laboratories:

• Reduced downtime and maintenance: Long injection sequences with stable performance reduce the need for frequent source/tube cleaning.
• High-throughput capability: Short LC methods and fast scan speeds enable large sample batches typical of clinical laboratories.
• Multiplexing and assay flexibility: The platform supports simultaneous quantification of small molecules, steroids and multiplexed peptide panels using SIL internal standards.
• Regulatory and QC compatibility: Ion ratio and retention time stability met criteria relevant to confirmatory toxicology and quantitative clinical assays.

Future trends and potential applications

Based on the study outcomes and current laboratory needs, likely future developments and uses include:

• Tighter integration with laboratory information systems (LIS) and automated QC/flagging for high-throughput clinical pipelines.
Expanded multiplexed peptide panels for targeted proteomics in routine clinical monitoring and precision medicine.
• Further optimization of low-flow/capillary LC–MS/MS to increase sensitivity while retaining throughput for limited-volume samples.
• Adoption of more automated sample preparation (robotics + filtered tip technologies) to minimize variability and labor.
• Enhanced software analytics, including AI-driven trend detection for predictive maintenance and batch-level QC.

Conclusions

The TSQ Certis triple quadrupole mass spectrometer demonstrated sustained robustness, reproducibility and operational stability across thousands of injections and multiple clinically relevant biomarker classes. Consistent peak-area performance, tight retention time control and stable ion ratios support its use in high-throughput clinical LC–MS/MS applications where minimal maintenance and reliable quantitative output are essential.

References

1. Patterson C., et al. Thermo Fisher Scientific technical note TN004362, 2026.
2. Guo J., et al. Thermo Fisher Scientific technical note TN004400, 2026.
3. Qin F., et al. Thermo Fisher Scientific technical note TN004401, 2026.
4. Qin F., et al. Angewandte Chemie International Edition, 2025.